ASCO Launches JCO Oncology Advances, Expanding Access to Groundbreaking Cancer Research

ALEXANDRIA, Va. - The American Society of Clinical Oncology (ASCO) proudly announces the publication of the first issue of JCO Oncology Advances (JCO OA), a new, fully open-access, interdisciplinary journal dedicated to publishing pioneering research in clinical and translational oncology. This launch marks a significant milestone in ASCO's commitment to enhancing accessibility to innovative cancer research worldwide.

"We are delighted to introduce the global oncology community to the first volume of JCO OA, which has been meticulously curated to foster progress and inspire innovation in cancer care," said Dr. Pamela Kunz, Editor-in-Chief of JCO Oncology Advances. "Our goal is to create a journal that not only disseminates cutting-edge research but also encourages a broader conversation about cancer treatment and patient care through open access."

Key Features and Innovations of JCO OA:

• Open Access Model: Unlike traditional subscription-based journals, JCO OA makes critical oncological research available through open access licenses, supporting ASCO's vision of conquering cancer through knowledge sharing.
• Diverse Content Types: The journal introduces novel article formats like Brief Reports and features new content like Plain Language Summaries, designed to bridge the gap between complex scientific data and practical application for patients.
• First Publication Highlights: The first articles feature a diverse range of impactful studies, including:
  • An exploration of racial disparities in the association between food swamps and early-onset colorectal cancer mortality.
  • An evaluation of the clinical outcomes and efficacy of HER2-targeted therapy in breast cancer with uncommon in situ hybridization patterns or discordant immunohistochemistry
  • A commentary discussing the new hope and challenges associated with small cell lung cancer treatment advancements
  • An editorial by the Editor-in-Chief outlining JCO OA's vision to advance oncology through broad access and inclusive science.

Dr. Kunz, a leader in medical oncology at the Yale School of Medicine, brings a wealth of experience and a visionary approach to her role as the first Editor-in-Chief. Under her leadership, the journal prioritizes inclusivity and diversity among its contributors and topics.

About the Submission Process: In addition to directly submitting to JCO OA, the journal offers a seamless cascade model, providing authors whose work is not accepted by the Journal of Clinical Oncology the option for an automatic transfer to JCO OA, streamlining the publication process.

Researchers and practitioners in oncology are encouraged to explore JCO OA's articles and consider the journal for their upcoming research submissions.

Founded in 1964, the American Society of Clinical Oncology, Inc. (ASCO®) is committed to the principle that knowledge conquers cancer. Together with the Association for Clinical Oncology, ASCO represents more than 50,000 oncology professionals who care for people living with cancer. Through research, education, and promotion of high quality, equitable patient care, ASCO works to conquer cancer and create a world where cancer is prevented or cured, and every survivor is healthy. Conquer Cancer, the ASCO Foundation, supports ASCO by funding groundbreaking research and education across cancer's full continuum. Learn more at www.ASCO.org, and follow us on Facebook, X, LinkedIn, Instagram, and YouTube.